Huang Chengyi, Chen Zhu, Liu Hao, He Junbo, Shen Yiwei, Wu Tingkui, Wang Beiyu
Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Department of Medical Engineering, West China Hospital, Sichuan University, Chengdu, China.
Spine (Phila Pa 1976). 2025 Mar 1;50(5):285-293. doi: 10.1097/BRS.0000000000005107. Epub 2024 Jul 29.
Prospective, randomized, parallel-controlled trial.
The primary aim of this study was to determine whether thrombin-gelatin matrix (TGM) combined with an absorbable gelatin sponge (AGS) could more greatly reduce intraoperative blood loss (IBL) in unilateral open-door laminoplasty than the sole use of an AGS could. The secondary aims were to evaluate the hemostatic efficiency, amount of postoperative bleeding, and safety of the application of TGM combined with an AGS.
IBL during cervical laminoplasty is substantial and is a proper indication for the application of hemostatic agents. However, we are unaware of any clinical trials on the application of TGM and an AGS in posterior cervical spine surgery.
A total of 80 consecutive patients who underwent unilateral open-door laminoplasty were enrolled from September 2020 to March 2022. Patients were randomized into 2 groups, the TGM-AGS group and the AGS group, with 40 patients in each group. The primary outcome was IBL. Other outcomes included the duration of operation, duration of hemostasis, duration of drainage, maximum decrease in hemoglobin (Hb), length of hospital stay, volume of drainage, number of drainage days, occurrence of adverse events, coagulation indicators, and patient-reported outcome measures (PROMs).
The mean IBL for patients in the TGM-AGS group (75.22 ± 21.83 mL) was significantly lower than that in the AGS group (252.43 ± 57.39 mL) (mean difference = 177.21 mL, 95% confidence interval [CI], 157.88-196.53 mL, t=18.25, P <0.001); the duration of hemostasis, volume of drainage, days of drainage in the TGM group, and maximum decrease in Hb were also significantly less than those in the AGS group ( P <0.01).
The hemostatic efficacy of TGM-AGS is better than that of an AGS alone in IBL. TGM-AGS is also superior to an AGS alone in the evaluation of hemostatic efficiency and postoperative bleeding.
前瞻性、随机、平行对照试验。
本研究的主要目的是确定凝血酶 - 明胶基质(TGM)联合可吸收明胶海绵(AGS)在单侧开门式椎板成形术中是否比单独使用AGS能更大程度地减少术中出血量(IBL)。次要目的是评估TGM联合AGS应用的止血效率、术后出血量及安全性。
颈椎椎板成形术中的IBL较多,是应用止血剂的合适指征。然而,我们尚未知晓关于TGM和AGS在颈椎后路手术中应用的任何临床试验。
2020年9月至2022年3月共纳入80例连续接受单侧开门式椎板成形术的患者。患者被随机分为两组,即TGM - AGS组和AGS组,每组40例。主要结局指标为IBL。其他结局指标包括手术时长、止血时长、引流时长、血红蛋白(Hb)最大降幅、住院时间、引流量、引流天数、不良事件发生率、凝血指标以及患者报告结局量表(PROMs)。
TGM - AGS组患者的平均IBL(75.22±21.83 mL)显著低于AGS组(252.43±57.39 mL)(平均差值 = 177.21 mL,95%置信区间[CI],157.88 - 196.53 mL,t = 18.25,P < 0.001);TGM组的止血时长、引流量及引流天数以及Hb最大降幅也显著少于AGS组(P < 0.01)。
在减少IBL方面,TGM - AGS的止血效果优于单独使用AGS。在止血效率和术后出血评估方面,TGM - AGS也优于单独使用AGS。